About the Startup
A Tirol-based MedTech startup focused on early detection and risk prediction of women’s cancers using epigenetic diagnostics. Its first product, the WID-easy Test, is a molecular PCR test that detects endometrial cancer from a simple self-collected vaginal swab. The company licenses its technology to partner laboratories and has expanded availability to the DACH region and the UK.
Frequently Asked Questions
What type of funding round did Sola Diagnostics raise?
Sola Diagnostics raised a grant round.
How much did Sola Diagnostics raise in its grant?
Sola Diagnostics raised $2,200,000 USD in its grant.
When did Sola Diagnostics raise its grant?
Sola Diagnostics raised its grant on 2025-09-30.
Who invested in Sola Diagnostics's grant?
The investors in Sola Diagnostics's grant are: Undisclosed UK grant provider.
What type of investment was Sola Diagnostics's grant?
Sola Diagnostics's grant was a equity investment.